BioSpace News Archive

Concert Pharmaceuticals, Inc. (NASDAQ:CNCE) today announced that its Phase 2 clinical trial to evaluate CTP-692 as an adjunctive treatment in patients with schizophrenia did not meet the primary endpoint or other secondary endpoints. CTP-692 is a deuterated form of D-serine

Sensei Biotherapeutics, Inc., a clinical-stage immunotherapy company focused on the discovery and development of next generation therapeutics for cancer, today announced that it has launched an underwritten initial public offering of 5,885,000 shares of its common stock at an anticipated initial public offering price between $16.00 and $18.00 per share

- Conference Call Today at 8 a.m. EST to Discuss Transaction - - Provides TEPEZZA® (teprotumumab-trbw) Supply Update; Submitted Prior Approval Supplement to FDA to Support Increased Scale Production of TEPEZZA -

Collaboration combines Sosei Heptares’ leading structure-based drug design platform with Metrion Biosciences’ ion channel expertise

Published Studies Explore How a Variant of p53 Contributes to the Development of Alzheimer’s Disease (AD) and How Plasma Levels of this Variant Can Serve as a Prognostic Biomarker Predicting Progression to AD Early in the Disease Process

Vicore Pharma Holding AB, a pharmaceutical company dedicated to developing innovative medicines for severe lung disorders, published data from the phase II study ATTRACT online and submitted it to a peer reviewed journal.

Quotient Limited, a commercial-stage diagnostics company, headquartered in Eysins, Switzerland, reported its third quarter fiscal 2021 results and other notable developments.

Exact Sciences Corp. announced that the company plans to release its fourth quarter 2020 financial results after the close of the U.S. financial markets on February 16, 2021.

Exact Sciences Corp. announced that company management will participate in the following conferences and invited investors to participate by webcast.

SIFI, a leading ophthalmic company, announced the publication of clinical results from its Phase I trial of polihexanide in healthy volunteers.